From 1 July 2018, maternal pertussis vaccine is being funded for pregnant women under the National Immunisation Program. AusVaxSafety is monitoring the safety of maternal pertussis vaccines in the days following immunisation. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

Last updated: 03/07/2020

11,704 Pregnant women responded to an SMS about their health a
few days after their maternal pertussis vaccinations.

93.8%
reported no adverse events

93.8%
reported no adverse events

6.2%
reported any adverse
event, including...

0.5%
who reported going
to a doctor or emergency
department in the days after
vaccination.

The adverse events they reported were similar to the types of adverse events reported overall

 

725 Pregnant women reported one or more adverse events.
The most commonly reported were:

These symptoms are known to occur after vaccination. They are generally mild and short-lived.

Surveillance of 2020 influenza vaccine safety commenced from 9 April 2020. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

Last updated 04/09/2020

4,095 Pregnant women responded to an SMS about their health a
few days after their influenza vaccinations.

95.0%
reported no adverse events

95.0%
reported no adverse events

5.0%
reported any adverse
event, including...

0.3%
who reported going
to a doctor or emergency
department in the days after
vaccination.

The adverse events they reported were similar to the types of adverse events reported overall

 

202 Pregnant women reported one or more adverse events.
The most commonly reported were:

These symptoms are known to occur after vaccination. They are generally mild and short-lived.